Canopy Growth (CGC) Cash & Equivalents (2017 - 2026)
Canopy Growth (CGC) posted Cash & Equivalents of $265.9 million for Q1 2026, little changed sequentially from $266.3 million in Q4 2025, and up 235.27% YoY from $79.3 million in Q1 2025.
Canopy Growth (CGC) Cash & Equivalents (2017 - 2026) Analysis & Trends
Canopy Growth has reported Cash & Equivalents for 10 years, with the latest figure at $265.9 million in Q1 2026.
- Quarterly Cash & Equivalents rose 235.27% year-over-year to $265.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265.9 million (up 235.27% YoY) and the FY2026 annual result came in at $265.9 million, up 235.27% from the prior year.
- Cash & Equivalents steadied at $265.9 million in Q1 2026 per CGC's latest filing, from $266.3 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $612.6 million in Q1 2022 and troughed at $79.3 million in Q1 2025.
- A 5-year average of $270.3 million and a median of $181.2 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2023 and 2026: Cash & Equivalents sank 76.21% in 2023, then surged 235.27% in 2026.
- Over 5 years, Cash & Equivalents stood at $440.6 million in 2022, then tumbled by 76.21% to $104.9 million in 2023, then increased by 10.54% to $115.9 million in 2024, then jumped by 129.74% to $266.3 million in 2025, then retreated by 0.13% to $265.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $265.9 million, $266.3 million, and $94.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Canopy Growth | 439.15 Mn | 192.14 Mn | 16.08 Mn | 243.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 243.35 Mn |
| Mar 31, 2026 | 265.93 Mn |
| Dec 31, 2025 | 266.27 Mn |
| Sep 30, 2025 | 94.07 Mn |
| Jun 30, 2025 | 91.08 Mn |
| Mar 31, 2025 | 79.32 Mn |
| Dec 31, 2024 | 115.90 Mn |
| Sep 30, 2024 | 167.44 Mn |
| Jun 30, 2024 | 140.49 Mn |
| Mar 31, 2024 | 126.38 Mn |
| Dec 31, 2023 | 104.85 Mn |
| Sep 30, 2023 | 181.24 Mn |
| Jun 30, 2023 | 396.99 Mn |
| Mar 31, 2023 | 335.19 Mn |
| Dec 31, 2022 | 440.64 Mn |
| Sep 30, 2022 | 572.54 Mn |
| Jun 30, 2022 | 603.55 Mn |
| Mar 31, 2022 | 612.64 Mn |
| Dec 31, 2021 | 488.02 Mn |
| Sep 30, 2021 | 641.58 Mn |